DURHAM, N.C., November 1, 2017 — Finding the optimal dose, dosing regimen — and, in a growing number of trials, the right combination treatment partner — is essential to developing an oncology therapeutic. Early-phase oncology trial designs must take into account the latest information about emerging therapies, biomarkers, and trial methodology, along with evolving regulations, to achieve right dose, schedule, and combination treatment regimen.
Premier Research will discuss these and other challenges in early Phase I/II oncology trials at a live webinar on Tuesday, November 7, at 11 a.m. EST / 4 p.m. GMT / 5 p.m. CST). This hour-long session will:
- Identify what is meant by the “right” dose, regimen, and potential combination treatment.
- Describe current regulatory and scientific/clinical factors affecting dose and regimen selection.
- Examine early-phase trial designs, such as 3+3, the continual reassessment method, and Bayesian designs for determining the optimum dose.
There’s much more, so register today.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatric, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.